Keene & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $3.5M | Buy |
61,881
+326
| +0.5% | +$18.4K | 2.81% | 11 |
|
|
2024
Q3 | $3.18M | Buy |
61,555
+1,242
| +2% | +$64.3K | 2.41% | 22 |
|
|
2024
Q2 | $2.5M | Buy |
60,313
+1,249
| +2% | +$51.9K | 2.04% | 30 |
|
|
2024
Q1 | $3.2M | Buy |
59,064
+11,219
| +23% | +$608K | 2.39% | 27 |
|
|
2023
Q4 | $2.45M | Buy |
47,845
+140
| +0.3% | +$7.18K | 2.04% | 28 |
|
|
2023
Q3 | $2.77M | Buy |
47,705
+2,494
| +6% | +$145K | 2.22% | 26 |
|
|
2023
Q2 | $2.89M | Buy |
45,211
+435
| +1% | +$27.8K | 2.25% | 26 |
|
|
2023
Q1 | $3.1M | Buy |
44,776
+1,497
| +3% | +$104K | 2.41% | 23 |
|
|
2022
Q4 | $3.11M | Sell |
43,279
-3,301
| -7% | -$238K | 2.78% | 16 |
|
|
2022
Q3 | $3.31M | Buy |
46,580
+7
| +0% | +$498 | 3.04% | 5 |
|
|
2022
Q2 | $3.59M | Sell |
46,573
-2,966
| -6% | -$228K | 3.36% | 3 |
|
|
2022
Q1 | $3.62M | Buy |
49,539
+2,040
| +4% | +$149K | 2.95% | 4 |
|
|
2021
Q4 | $2.96M | Buy |
+47,499
| New | +$2.96M | 2.56% | 17 |
|